Related Experiment Video

Updated: May 4, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.7K

Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin

James H Flory1, Dylan S Small, Patricia A Cassano

  • 1Weill Cornell Medical College, 525 East 68th Street, Baker Pavilion 20th Floor, NY 10021, USA.

Journal of Comparative Effectiveness Research
|December 19, 2013
PubMed
Abstract

Insights

Adding a second or third oral diabetes medication to metformin can lower glycosylated hemoglobin. Effectiveness varies by drug combination, baseline levels, and patient factors like sex and BMI.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Clinical Medicine

Background:

  • Type 2 diabetes management often involves combination oral pharmacotherapy.
  • Evidence on the comparative effectiveness of these combinations is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To evaluate the comparative effectiveness of dual- and triple-drug oral diabetes treatment regimens.
  • To assess factors influencing treatment response in a real-world clinical setting.

Main Methods:

  • Retrospective observational cohort study design.
  • Analysis of glycosylated hemoglobin (HbA1c) change in outpatients.
  • Inclusion of patients initiating dual- or triple-drug oral diabetes therapy.

Main Results:

  • Adding a second drug to metformin resulted in an adjusted HbA1c decline of 0.85% to 1.21%.
  • Adding a third drug yielded a smaller HbA1c decline of 0.53% to 0.91%.
  • Higher baseline HbA1c, sulfonylurea effectiveness over time, and differential effectiveness of thiazolidinediones in specific patient subgroups (obese, women) were observed.

Conclusions:

  • Observational data align with existing randomized trial findings on oral diabetes drug effectiveness.
  • These findings extend evidence to clinical scenarios lacking randomized data.
  • Patient sex and body mass index (BMI) significantly impact the comparative effectiveness of oral diabetes drug combinations.

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.5K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.2K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
953
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K